Avanos Medical Inc. (AVNS)

Natixis Advisors L.P. Makes New Investment in Avanos Medical, Inc. (NYSE:AVNS)

Natixis Advisors L.P. bought a new stake in shares of Avanos Medical, Inc. (NYSE:AVNS – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 14,142 shares of the company’s stock, valued at approximately $317,000. A number of other hedge funds and other institutional investors also recently made changes to their positions in AVNS. William Blair Investment Management LLC purchased a new position in shares of Avanos Medical in the 3rd quarter valued at approximately $22,134,000. RGM Capital LLC lifted its position in Avanos Medical by 6.8% during the third quarter. RGM Capital LLC now owns 2,951,691 shares of the company’s stock valued at $59,683,000 after buying an additional 189,017 shares during the period. Foundry Partners LLC boosted its holdings in shares of Avanos Medical by 74.6% during the 4th quarter. Foundry Partners LLC now owns 371,029 shares of the company’s stock valued at $8,322,000 after buying an additional 158,473 shares in the last quarter. Kestrel Investment Management Corp purchased a new stake in shares of Avanos Medical in the 4th quarter worth about $3,265,000. Finally, Jupiter Asset Management Ltd. increased its stake in shares of Avanos Medical by 234.2% in the 3rd quarter. Jupiter Asset Management Ltd. now owns 149,983 shares of the company’s stock worth $3,033,000 after acquiring an additional 105,100 shares in the last quarter. Institutional investors own 95.17% of the company’s stock. Wall Street Analysts Forecast Growth Several equities research analysts recently commented on the stock. JMP Securities reissued a “market perform” rating on shares of Avanos Medical in a research note on Tuesday, May 7th. StockNews.com upgraded Avanos Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 11th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Avanos Medical currently has an average rating of “Moderate Buy” and a consensus target price of $31.00. Read Our Latest Stock Report on Avanos Medical Insider Activity In related news, CFO Michael Greiner sold 8,000 shares of Avanos Medical stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $19.12, for a total transaction of $152,960.00. Following the transaction, the chief financial officer now directly owns 151,495 shares in the company, valued at $2,896,584.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.90% of the company’s stock. Avanos Medical Stock Performance Shares of AVNS stock opened at $20.39 on Monday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.47 and a current ratio of 2.28. The company has a market capitalization of $935.98 million, a price-to-earnings ratio of -15.33 and a beta of 0.97. Avanos Medical, Inc. has a one year low of $17.24 and a one year high of $26.56. The company’s 50-day moving average is $19.34 and its 200 day moving average is $20.02. Avanos Medical (NYSE:AVNS – Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.02). The firm had revenue of $166.10 million for the quarter, compared to the consensus estimate of $162.90 million. Avanos Medical had a negative net margin of 9.15% and a positive return on equity of 4.10%. Avanos Medical’s revenue was up 4.3% on a year-over-year basis. During the same period last year, the business earned $0.27 EPS. Sell-side analysts expect that Avanos Medical, Inc. will post 1.38 EPS for the current fiscal year. Avanos Medical Profile (Free Report) Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.